Atomoxetine and Panobinostat: Interaction Details
- Atomoxetine
- StratteraAtoncy
- Panobinostat
- Farydak
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Atomoxetine and Panobinostat interaction:
Atomoxetine
- Strattera
- Atoncy
Panobinostat
- Farydak
We don't have a drug information page for Panobinostat yet. Have a question about Panobinostat? Ask a pharmacist, free →
What Happens When You Take Atomoxetine With Panobinostat
What can happen when they are taken together (rated Major)
Increased exposure
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
One study found that giving dextromethorphan (a CYP2D6 substrate) together with panobinostat (a CYP2D6 ) raised dextromethorphan exposure, with a very wide range of variability between subjects. Because the exposure of a CYP2D6 substrate may rise, panobinostat should not be combined with sensitive CYP2D6 substrates or with CYP2D6 substrates that have a . When the combination cannot be avoided, close and frequent monitoring is recommended.1
The Atomoxetine and Panobinostat Interaction, Explained
Atomoxetine (Strattera) is mostly cleared from your body by an enzyme called . Panobinostat (Farydak), a cancer medicine, can slow that enzyme down. That means atomoxetine could build up in your body and may cause more side effects, such as a faster heartbeat, higher blood pressure, trouble sleeping, nausea, or feeling dizzy or jittery.
This concern is mostly based on how panobinostat affected a different drug cleared the same way, so it is theoretical for atomoxetine, and the effect varied a lot between people. Please keep taking both as prescribed and talk with your pharmacist or doctor. Your care team can manage this by adjusting and individualizing doses and monitoring you more closely.
Mechanism: Panobinostat inhibits , the primary pathway of atomoxetine (active drug, not a ), so atomoxetine exposure (, ) may rise, as with poor-metabolizer status.
- Evidence: Theoretical for atomoxetine. One PK study with dextromethorphan showed highly variable increases in exposure.
- Onset: Unspecified.
- Risks: Increased noradrenergic effects: , hypertension, insomnia, upset, urinary hesitancy, mood changes.
- Management: Labeling advises avoiding panobinostat with sensitive CYP2D6 or those with a . If is unavoidable, monitor frequently (heart rate, blood pressure, tolerability) and individualize atomoxetine dosing.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Atomoxetine and Panobinostat Interact
The likely mechanism
of -mediated by panobinostat
How to Manage the Atomoxetine and Panobinostat Interaction
The documented advice is to avoid combining panobinostat with medicines cleared by , like atomoxetine, when possible. If both are needed, your care team will usually monitor you more frequently.
- Keep taking both medicines as prescribed. Do not stop or change either one on your own.
- Your care team may adjust and individualize the atomoxetine dose, or consider another option.
- Tell your pharmacist or prescriber about palpitations, high blood pressure readings, trouble sleeping, nausea, or feeling unusually jittery or dizzy.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Atomoxetine or Panobinostat need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: FARYDAK oral capsules, panobinostat oral capsules
In 1 study, giving dextromethorphan together with panobinostat produced highly variable increases in dextromethorphan exposure. In patients with advanced cancer, a single dose of dextromethorphan (a ) was added to an existing panobinostat 20 mg regimen (n=14), and the and of dextromethorphan rose from baseline by 80% (interquartile ranges: 20% to 200%) and 60% (interquartile ranges: 20% to 130%), respectively.1
Atomoxetine and Panobinostat: Common Questions
How serious is the Atomoxetine and Panobinostat interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Atomoxetine and Panobinostat interaction managed?
The documented advice is to avoid combining panobinostat with medicines cleared by , like atomoxetine, when possible. If both are needed, your care team will usually monitor you more frequently. Keep taking both medicines as prescribed. Do not stop or change either one on your own. Your care team may adjust and individualize the atomoxetine dose, or consider another option. Tell your pharmac… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Atomoxetine and Panobinostat Interaction
Ask in your own words about taking Atomoxetine and Panobinostat together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: FARYDAK(R) oral capsules, panobinostat oral capsules. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2015. DailyMed
Other Serious Interactions of Atomoxetine and Panobinostat
Also serious with Atomoxetine
- Linezolid InjectionContraindicated
- IsocarboxazidContraindicated
- LinezolidContraindicated
- Methylene BlueContraindicated
Also serious with Panobinostat
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Atomoxetine
- Activated CharcoalMajor
- Black PepperModerate
- GrapeModerate
- QuercetinModerate
- PomegranateModerate
- BerberineModerate
- Boswellia SerrataModerate
- Slippery ElmModerate
- + 69 more
With Panobinostat
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- Sida CordifoliaMajor
- + 150 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.